Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ligand Pharm
(NQ:
LGND
)
73.90
+1.58 (+2.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ligand Pharm
< Previous
1
2
3
Next >
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 16, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2023 Financial Results
May 04, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
April 24, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Fourth Quarter Financial Results on February 22
February 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
January 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Provides Highlights from its Investor and Analyst Day Event
December 13, 2022
From
Ligand Pharmaceuticals
Via
Business Wire
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
December 05, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Hold Investor and Analyst Day on December 13
November 16, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Announces Completion of OmniAb Spin-Off
November 01, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Distribution of OmniAb Complete and Business Combination Closed
November 01, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Third Quarter Financial Results on November 7
October 26, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
October 26, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
OmniAb Business Combination Approved by APAC Shareholders
October 24, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
October 03, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
August 24, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 01, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Second Quarter Financial Results on August 8
July 22, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
June 29, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2022 Financial Results
May 04, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter Financial Results on May 4
April 19, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
March 23, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Fourth Quarter Financial Results on February 17
February 09, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
December 22, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.